Introduction: Gastric cancer (GC) is the fifth most common type of cancer and the fourth leading cause of death related to this disease. In the north of Brazil, this type of cancer is the second most common in men and the fifth in women, which suggests that there may be a genetic influence contributing to this carcinogenesis process. Studies indicate that some genetic factors are important for the development of GC, for example, alterations in important genes such as CDH1, a tumor suppressor gene responsible for producing E-cadherin, a cell adhesion protein that plays an important role in cell growth and differentiation.
Objectives: To investigate genetic variants in the CDH1 gene in a mixed-race population with gastric cancer, and to compare the allele frequency found with the frequency of the world population.
Methods: The population consisted of 107 admixed individuals diagnosed with GC, treated at the João de Barros Barreto University Hospital. Genetic material was extracted from peripheral blood using the Biopur Mini Spin Plus 250 Extraction Kit and DNA. DNA quantification was performed using a Nanodrop8000 spectrophotometer (Thermo Fisher Scientific Inc., Wilmington, DE, USA) and quality analysis was performed by 2% agarose gel electrophoresis. The variant library (exome) was prepared using Nextera Rapid Capture Exome (Illumina®, San Diego, CA, USA) and SureSelect Human All Exon V6 (Agilent Technologies, Santa Clara, CA, USA), following the kit protocol provided by the manufacturer. The sequencing reaction was performed by the NextSeq 500® platform (Illumina®, San Diego, CA, USA) using the NextSeq 500 High-output v2 Kit 300 cycle (Illumina®, San Diego, CA, USA). The study was approved by the National Research Ethics Commission (CONEP) and by the Research Ethics Committee of the Institute of Health Sciences of the Federal University of Pará (CAAE: 43199815.9.0000.0018). The frequencies of the variants found were compared with those of other populations using data from the 1000 genomes platform from phase 3. Fisher's Exact Test (statistical program Rstudio v.4.1.2) was used to analyze the results considering p-value ? 0.05 as statistically significant data.
Results: From the exome analysis and according to SNPeff (which predicts effects of genetic variants, such as amino acid changes), two low-impact variants (rs33964119 and rs1801552) were found in the CDH1 gene. Regarding the rs33964119 variant, it was observed that only the European (p=0.001) and South Asian (p=0.037) populations were genetically distinct from the mixed-race population evaluated. For the rs1801552 variant, it was also observed that the most genetically distinct population from the mixed-race populations were the Europeans (p=8.49E-18), but, in this second analysis, the American population was more distinct than the South Asians (p=0.008).
Conclusion: Only two low-impact variants in one of the genes related to CG susceptibility were found, which raises the possibility that other genes or environmental factors may be contributing to the development of this disease. In addition, it was found that the mixed-race population of the Brazilian Amazon is considerably genetically distinct from the European, South Asian and American populations, based on the allele frequencies of the variants analyzed.
It is with great enthusiasm that we present the Annals of the Oncology International Symposium 2025, an event that continues to solidify its significance in the oncology landscape of northern Brazil. Held in Belém, Pará, Oncology 2025 centered around the theme "The cancer control challenge: better knowing it to best facing it," dedicating itself to exploring the latest frontiers in cancer treatment and prevention.
This year, the symposium provided a deep dive into the essential role of knowledge in the fight against cancer, presenting new perspectives and scientific advancements across various areas of oncology. Renowned global experts gathered to share their most recent research and innovative approaches, offering participants a comprehensive view of the challenges faced by healthcare professionals and patients worldwide.
Presentations and discussions during the event focused on critical topics such as the use of new technologies, advancements in personalized therapies, and more effective prevention strategies. Additionally, particular attention was given to the unique challenges faced by the Amazon region, with efforts aimed at developing region-specific solutions to meet local needs.
Beyond being a high-caliber academic event, Oncology 2025 stood out as a moment for integration and professional networking, with the warm hospitality of the city of Belém offering participants a unique experience. This event became a platform for exchanging ideas, where science, culture, and humanity came together in pursuit of a common goal: to improve cancer control both in Brazil and globally.
This collection of abstracts and articles presented during the event reflects the ongoing dedication to research and the development of innovative solutions, highlighting the importance of collaboration and shared knowledge in the fight against cancer.
General Submission Guidelines:
The presenting author, who does not have to be the first author, must be registered for Oncology 2025.
Each abstract may have up to 10 authors, including the main author and co-authors.
Only original, unpublished work will be accepted.
Submissions must be related to oncology. However, project descriptions, work proposals, experience reports, and literature reviews will not be considered.
Clinical case reports are allowed, provided the abstract addresses scientific questions, details clinical observations, and includes primary scientific data.
The abstract must be written in English, but presentations may be given in Portuguese.
Abstracts must be between 300 and 500 words.
Comissão Organizadora
Comissão Científica
See Annals of Oncology 2023 at:
https://www.even3.com.br/anais/oncology-2023-international-symposium/